HHS Peptide Docket Hits 12 Comments. What That Decides

Summary. The Federal Register record for HHS's notice of availability on 503A compounding with certain peptide bulk drug substances (FR Doc. 2026-22192, published 30 October 2026 at 91 FR 68526) now carries a regulations.gov comment count of 12, as of the API refresh checked on the morning of 5 November 2026 (UTC). That is a change from earlier in the window, when the public docket still showed no posted comments. The docket (HHS-OASH-2026-0496) remains open for written comments until 11:59 p.m. Eastern on 13 November 2026, and late comments are not accepted. Our FDA Peptide Compounding Policy Tracker follows each step.

Research context (RUO). A comment filed on this nonrulemaking docket goes into a record that HHS says FDA may consider in future rulemaking on the 503A bulks list. It is not a vote, it does not itself add any substance to that list, and it does not turn the interim enforcement-discretion policy into an FDA approval of any compounded product. The notice is a notice of availability: it points to the HHS policy PDF, creates no rights for any person, and is not binding on HHS or the public. HHS may revisit the policy if a safety signal or product-quality issue arises. For laboratories reading lot paperwork, the policy's documentation conditions still point back to a full certificate of analysis; our COA page and the Academy chapter on basic terms explain that vocabulary. These rules concern compounding for patients, not research-grade material.

This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.